Section of Digestive Diseases, Yale Liver Center, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Section of Digestive Diseases, Yale Liver Center, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Cell Mol Gastroenterol Hepatol. 2019;8(2):197-207. doi: 10.1016/j.jcmgh.2019.04.013. Epub 2019 May 7.
Cystic fibrosis (CF) is a monogenic disease caused by mutation of Cftr. CF-associated liver disease (CFLD) is a common nonpulmonary cause of mortality in CF and accounts for approximately 2.5%-5% of overall CF mortality. The peak of the disease is in the pediatric population, but a second wave of liver disease in CF adults has been reported in the past decade in association with an increase in the life expectancy of these patients. New drugs are available to correct the basic defect in CF but their efficacy in CFLD is not known. The cystic fibrosis transmembrane conductance regulator, expressed in the apical membrane of cholangiocytes, is a major determinant for bile secretion and CFLD classically has been considered a channelopathy. However, the recent findings of the cystic fibrosis transmembrane conductance regulator as a regulator of epithelial innate immunity and the possible influence of the intestinal disease with an altered microbiota on the liver complication have opened new mechanistic insights on the pathogenesis of CFLD. This review provides an overview of the current understanding of the pathophysiology of the disease and discusses a potential target for intervention.
囊性纤维化(CF)是一种由 Cftr 基因突变引起的单基因疾病。CF 相关肝病(CFLD)是 CF 患者非肺部死亡的常见原因,约占 CF 总死亡率的 2.5%-5%。该病的发病高峰在儿科人群中,但在过去十年中,与这些患者预期寿命的增加相关,已报告 CF 成人中出现第二波肝病。有新的药物可纠正 CF 中的基本缺陷,但它们在 CFLD 中的疗效尚不清楚。囊性纤维化跨膜电导调节因子(CFTR)表达在胆管细胞的顶膜上,是胆汁分泌的主要决定因素,CFLD 经典上被认为是一种通道病。然而,最近发现 CFTR 作为上皮固有免疫的调节剂,以及肠道疾病中改变的微生物群对肝脏并发症的可能影响,为 CFLD 的发病机制提供了新的机制见解。本文综述了目前对该病病理生理学的认识,并讨论了一种潜在的干预靶点。